Physician profile
Gowri Ramadas
NPI 1528294998
$31,304.84
in general payments reported to CMS, 2019-2025
74 companies · $4,378 in 2025
The $4,378 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,338 · 2020: $485 · 2021: $6,648 · 2022: $6,147 · 2023: $4,270 · 2024: $6,039 · 2025: $4,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,327 · Food and Beverage: $7,240 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,326.50 |
| Food and Beverage | $7,240.22 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $11,459.30 | 2021-2025 | Datroway, Enhertu, Vanflyta |
| Seagen INC. | $1,754.68 | 2019-2023 | Padcev, Tukysa |
| Karyopharm Therapeutics INC. | $1,580.95 | 2021-2024 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $1,334.09 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,307.96 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $1,151.43 | 2019-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $992.27 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $959.43 | 2019-2025 | Venclexta, Avastin, Tecentriq |
| Tosoh Bioscience, INC. | $948.00 | 2019 | |
| Celgene Corporation | $804.12 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $763.79 | 2019-2025 | |
| Pfizer INC. | $723.70 | 2019-2025 | |
| Janssen Biotech, INC. | $639.88 | 2019-2025 | Erleada, Balversa, Akeega |
| Amgen INC. | $501.09 | 2019-2023 | Lumakras, Kyprolis |
| Gilead Sciences, INC. | $469.89 | 2021-2025 | Trodelvy |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gowri Ramadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.